Clinical trials: Polycystic Kidney Diseases
ADPKD
Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
The objective of this study is to measure the influence of both short term water restriction and high water intake on total kidney volume, measured by Magnetic Resonance Imaging (MRI) scan in Autosomal Dominant Polycystic Kidney…
- Trial name
- NCT02776241
- Testing
- water
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
ADPKD
Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?
The investigators are running a study to see if a special drink, called a "ketone ester", can help people with a type of kidney disease named "Autosomal Dominant Polycystic Kidney Disease" or ADPKD for short.
- Trial name
- ADKETONE (NCT06100133)
- Testing
- Ketone ester
- Volunteers
- 20 people
- Sponsor
- Universitair Ziekenhuis Brussel
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Tolvaptan Extension Study in Participants With ADPKD
To demonstrate whether tolvaptan modifies ADPKD progression as measured by changes from Baseline (from Study 156-04-251) in total kidney volume (TKV) and renal function.
- Trial name
- TEMPO 4/4 (NCT01214421)
- Testing
- Tolvaptan
- Where
- 97 sites in United States, Argentina and 11 more
- Volunteers
- 1,083 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Polycystic Kidney, Autosomal Recessive
A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
This study evaluates safety and tolerability of a single ascending dose of a tesevatinib liquid formulation administered to pediatric subjects with ARPKD.
- Trial name
- NCT03096080
- Testing
- Tesevatinib
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Kadmon Corporation, LLC
Autosomal Recessive Polycystic Kidney Disease
Imaging Assessments of ARPKD Kidney Disease Progression
Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a potentially lethal genetic disorder for which there are currently no disease specific treatments.
- Trial name
- IMAGE-ARPKD (NCT07201025)
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Polycystic Kidney
Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease
Triptolide has been approve effective in animal model.
- Trial name
- NCT00801268
- Testing
- tripterygium wilfordii, Emodin
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Zhi-Hong Liu, M.D.
Autosomal Dominant Polycystic Kidney Disease
A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
This is a prospective, non-interventional study (NIS) measuring health-related quality of life (HRQoL), treatment satisfaction, and other patient-reported outcomes (PROs) of ADPKD patients in Europe.
- Trial name
- ACQUIRE (NCT02848521)
- Where
- 26 sites in Austria, Belgium and 5 more
- Volunteers
- 407 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Autosomal Dominant Polycystic Kidney Disease
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The purpose of the trial was to determine the short-term effects of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) at various levels of renal function.
- Trial name
- NCT01336972
- Testing
- Tolvaptan
- Where
- Netherlands
- Volunteers
- 29 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Chronic Kidney Diseases, Diabetes
KidneYou - Innovative Digital Therapy
The aim of the study is to assess the improvement of health in patients affected by CKD when they are exposed to non-pharmacological treatment strategies as nutritional program (NP), physical activity program (PA) and mindfulness…
- Conditions
- Chronic Kidney Diseases, Diabetes, Arterial Hypertension, Chronic Glomerulonephritis
- Trial name
- NCT05286632
- Testing
- KidneYou APP
- Where
- Italy
- Volunteers
- 210 people
- Sponsor
- Advice Pharma Group srl
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
The German ADPKD Tolvaptan Treatment Registry
The German ADPKD Tolvaptan Treatment Registry is a prospective, observational, multicentric study of patients suffering from ADPKD that are considered for tolvaptan treatment.
- Trial name
- AD(H)PKD (NCT02497521)
- Where
- 12 sites in Germany
- Volunteers
- 2,000 people
- Sponsor
- University of Cologne
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Canadian Medical Assessment of JINARC™ Outcomes Registry
This study is part of the Health Canada approval requirement for JINARC™ (tolvaptan) and is an observational, non-interventional study (NIS) describing the impact of tolvaptan on ADPKD-related burden of illness as measured with a…
- Trial name
- C-MAJOR (NCT02925221)
- Where
- 6 sites in Canada
- Volunteers
- 530 people
- Sponsor
- Otsuka Canada Pharmaceutical Inc.
Polycystic Liver Disease
Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
This Pilot study will enable development \& assessment of a Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q).
- Trial name
- NCT02173080
- Testing
- PLD-Q
- Where
- United States
- Volunteers
- 594 people
- Sponsor
- Mayo Clinic
Polycystic Liver Disease
Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
The aim of this study is to determine the effect of Lanreotide on polycystic liver and kidneys in patients with autosomal dominant polycystic kidney disease.
- Trial name
- RESOLVE (NCT01354405)
- Testing
- Lanreotide
- Where
- Netherlands
- Volunteers
- 43 people
- Sponsor
- Radboud University Medical Center
ADPKD
Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder occurring in 1:400-1:1.000 live births and affects 4 to 6 million persons worldwide and about 205.000 people in Europe (EU).
- Trial name
- METROPOLIS (NCT03764605)
- Testing
- Metformin, Tolvaptan
- Where
- 2 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults
The primary objective of this study is to assess the effect of a therapeutic and supratherapeutic oral dose of JMKX003142 on the corrected cardiac QT interval relative to a placebo in healthy participants
- Trial name
- NCT07470177
- Testing
- JMKX003142 tablets
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jemincare
Polycystic Kidney, Autosomal Dominant
The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
This pilot study will compare endothelial function in patients with ADPKD with matched healthy volunteers and normotensive chronic kidney disease stage 1 \& 2 patients.
- Trial name
- NCT04023214
- Testing
- Peripheral (digital) arterial tonometry
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Polycystic Kidney Disease
Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
Funding Source - FDA OOPD Pioglitazone is currently used in clinical practice to treat diabetes and this study will examine the potential use of a low dose of the same drug for the treatment of polycystic kidney disease.
- Trial name
- PIOPKD (NCT02697617)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Indiana University
Autosomal Dominant Polycystic Kidney
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
The EMPA-PKD trial is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring kidney growth and the rate of loss of kidney function.
- Trial name
- EMPA-PKD (NCT06391450)
- Testing
- Empagliflozin 10 MG
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Hannover Medical School
Autosomal Dominant Polycystic Kidney Disease
NOX4 and Related Biomarkers in ADPKD
To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT04630613
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney Disease
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
Investigation into the long-term safety and efficacy of OPC-41061 in repeated oral administrations at doses of 15 mg twice daily in patients with ADPKD who completed the preceding dose-finding study (156-04-001).
- Trial name
- NCT00841568
- Testing
- OPC-41061
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.